Spinnaker Opportunities PLC Additional Subscription (9445I)
06 Aprile 2020 - 4:21PM
UK Regulatory
TIDMSOP
RNS Number : 9445I
Spinnaker Opportunities PLC
06 April 2020
6 April 2020
Spinnaker Opportunities plc
("Spinnaker" or the "Company")
Additional Subscription
Further to the announcement made on 19 March, Spinnaker is
pleased to confirm that a further loan note subscription of
GBP40,000 has been received from two investors under the same
terms.
The loan notes will convert into 800,000 shares ("Subscription
Shares") at a conversion price of 5p per share on the date on which
the Company's shares are re-admitted to trading and the investors
shall be entitled to receive one warrant for every two Subscription
Shares issued ("Warrants"). The Warrants will be issued at a strike
price of 5p and with validity of 3 years from the date of
re-admission.
For further information, please visit
http://www.spinnakeropportunities.uk/ or contact the following:
Peterhouse Capital (Financial Adviser and Joint Broker)
Tel: +44 (0)20 7469 0930
Guy Miller/ Lucy Williams / Eran Zucker
SI Capital (Joint Broker)
Tel: +44 (0)1483 413 500 / +44 (0) 203 871 4038
Nick Emerson / Greg Mahoney
Blytheweigh (Financial PR)
Tel: +44 (0) 207 138 3224
Camilla Horsfall / Megan Ray
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have
been deemed inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 until the release of this
announcement.
Notes to Editors
Kanabo is an Israel based company, that believes that by
creating a holistic ecosystem that works together in synergy, it
can create a new standard in the medical Cannabis industry and
improve the well-being of millions around the world. Kanabo will
focus on the distribution of Cannabis-derived products for medical
patients, and THC-free CBD products for consumers. Kanabo has
conducted extensive R&D in order to develop high-quality
Cannabis extract formulas, innovative medical-grade vaporizers, and
various non-smoking consumption solutions - making it easy and
accessible for anyone in need of treatment. Research and validation
activities, including safety and efficiency tests, are conducted in
the company's research centre in Israel.
Kanabo is currently undertaking a pilot sales scheme to measure
key performance indicators in relation to the sale of its range of
THC-free CBD products. It is ready to scale up to meet market
demands and projected sales and revenues and to grow the Kanabo
brand through its marketing initiatives.
Kanabo's future long-term strategy involves continued research
and development activities to develop a range of Unlicensed Medical
Cannabis Oils, which will be sold alongside its vaporisation
device, the VapePod Medical. It is intended that medicinal products
will be sold as unlicensed medicines in the UK and Germany.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCIFMITMTBMBPM
(END) Dow Jones Newswires
April 06, 2020 10:21 ET (14:21 GMT)
Grafico Azioni Spinnaker Opportunities (LSE:SOP)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Spinnaker Opportunities (LSE:SOP)
Storico
Da Apr 2023 a Apr 2024